{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:49:11Z","timestamp":1790596151596,"version":"4.1.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10463-w","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T06:57:01Z","timestamp":1743231421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Molecular mechanisms and biomarkers in neurodegenerative disorders: a comprehensive review"],"prefix":"10.1007","volume":"52","author":[{"given":"Nisha","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Sayeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Monowar Alam","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Kalim Ahmad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"10463_CR1","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jconrel.2020.11.021","volume":"330","author":"A Akhtar","year":"2021","unstructured":"Akhtar A, Andleeb A, Waris TS, Bazzar M, Moradi A-R, Awan NR et al (2021) Neurodegenerative diseases and effective drug delivery: a review of challenges and novel therapeutics. J Control Release 330:1152\u20131167","journal-title":"J Control Release"},{"key":"10463_CR2","first-page":"1","volume":"20","author":"A Suganya","year":"2023","unstructured":"Suganya A, Aarthy SL (2023) Application of deep learning in the diagnosis of Alzheimer\u2019s and parkinson\u2019s disease: a review. Curr Med Imaging Former Curr Med Imaging Rev 20:1\u201318","journal-title":"Curr Med Imaging Former Curr Med Imaging Rev"},{"key":"10463_CR3","doi-asserted-by":"crossref","first-page":"8609","DOI":"10.1523\/JNEUROSCI.2532-06.2006","volume":"26","author":"YM Ganat","year":"2006","unstructured":"Ganat YM, Silbereis J, Cave C, Ngu H, Anderson GM, Ohkubo Y et al (2006) Early postnatal astroglial cells produce multilineage precursors and neural stem cells in vivo. J Neurosci 26:8609\u20138621","journal-title":"J Neurosci"},{"key":"10463_CR4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/ijms23031851","volume":"23","author":"RNL Lamptey","year":"2022","unstructured":"Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J (2022) A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci 23:1851","journal-title":"Int J Mol Sci"},{"key":"10463_CR5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/35040009","volume":"1","author":"MP Mattson","year":"2000","unstructured":"Mattson MP (2000) Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1:120\u2013130","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10463_CR6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-1-0716-3774-6_15","volume":"2785","author":"SM Gentleman","year":"2024","unstructured":"Gentleman SM, Liu AKL (2024) Neuropathological assessment as an endpoint in clinical trial design. Methods Mol Biol 2785:261\u2013270","journal-title":"Methods Mol Biol"},{"key":"10463_CR7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cm.21822","volume":"81","author":"K Iqbal","year":"2024","unstructured":"Iqbal K (2024) Tau and Alzheimer\u2019s disease: past, present and future. Cytoskeleton 81:116\u2013121","journal-title":"Cytoskeleton"},{"key":"10463_CR8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3390\/jcm9041061","volume":"9","author":"M Sharifi-Rad","year":"2020","unstructured":"Sharifi-Rad M, Lankatillake C, Dias DA, Docea AO, Mahomoodally MF, Lobine D et al (2020) Impact of natural compounds on neurodegenerative disorders: from preclinical to pharmacotherapeutics. J Clin Med 9:1061","journal-title":"J Clin Med"},{"key":"10463_CR9","doi-asserted-by":"publisher","DOI":"10.31083\/j.jin2203058","author":"J Liu","year":"2023","unstructured":"Liu J, Duan W, Deng Y, Zhang Q, Li R, Long J et al (2023) New insights into molecular mechanisms underlying neurodegenerative disorders. J Integr Neurosci. https:\/\/doi.org\/10.31083\/j.jin2203058","journal-title":"J Integr Neurosci"},{"key":"10463_CR10","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.biopha.2018.12.133","volume":"111","author":"M Saeedi","year":"2019","unstructured":"Saeedi M, Eslamifar M, Khezri K, Dizaj SM (2019) Applications of nanotechnology in drug delivery to the central nervous system. Biomed Pharmacother 111:666\u2013675","journal-title":"Biomed Pharmacother"},{"key":"10463_CR11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13195-022-00963-3","volume":"14","author":"H Liu","year":"2022","unstructured":"Liu H, Hu Y, Zhang Y, Zhang H, Gao S, Wang L et al (2022) Mendelian randomization highlights significant difference and genetic heterogeneity in clinically diagnosed Alzheimer\u2019s disease GWAS and self-report proxy phenotype GWAX. Alzheimers Res Ther 14:17","journal-title":"Alzheimers Res Ther"},{"key":"10463_CR12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40142-018-0133-1","volume":"6","author":"N Jain","year":"2018","unstructured":"Jain N, Chen-Plotkin AS (2018) Genetic modifiers in neurodegeneration. Curr Genet Med Rep 6:11\u201319","journal-title":"Curr Genet Med Rep"},{"key":"10463_CR13","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/ijms21041375","volume":"21","author":"Z Miao","year":"2020","unstructured":"Miao Z, Wang Y, Sun Z (2020) The relationships between stress, mental disorders, and epigenetic regulation of BDNF. Int J Mol Sci 21:1375","journal-title":"Int J Mol Sci"},{"key":"10463_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2525967","author":"Z Liu","year":"2017","unstructured":"Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L (2017) Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxid Med Cell Longev. https:\/\/doi.org\/10.1155\/2017\/2525967","journal-title":"Oxid Med Cell Longev"},{"key":"10463_CR15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q (2022) Alzheimer\u2019s disease: epidemiology and clinical progression. Neurol Ther 11:553\u2013569","journal-title":"Neurol Ther"},{"key":"10463_CR16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13024-020-00391-7","volume":"15","author":"T Guo","year":"2020","unstructured":"Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y (2020) Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer\u2019s disease. Mol Neurodegener 15:40","journal-title":"Mol Neurodegener"},{"key":"10463_CR17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113320","volume":"216","author":"S Srivastava","year":"2021","unstructured":"Srivastava S, Ahmad R, Khare SK (2021) Alzheimer\u2019s disease and its treatment by different approaches: a review. Eur J Med Chem 216:113320","journal-title":"Eur J Med Chem"},{"key":"10463_CR18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.neuron.2014.05.004","volume":"82","author":"TL Spires-Jones","year":"2014","unstructured":"Spires-Jones TL, Hyman BT (2014) The Intersection of amyloid beta and tau at synapses in Alzheimer\u2019s disease. Neuron 82:756\u2013771","journal-title":"Neuron"},{"key":"10463_CR19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener 14:32","journal-title":"Mol Neurodegener"},{"key":"10463_CR20","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/biomedicines10071760","volume":"10","author":"D Kon\u00ed\u010dkov\u00e1","year":"2022","unstructured":"Kon\u00ed\u010dkov\u00e1 D, Men\u0161\u00edkov\u00e1 K, Tu\u010dkov\u00e1 L, H\u00e9nykov\u00e1 E, Strnad M, Friedeck\u00fd D et al (2022) Biomarkers of neurodegenerative diseases: biology, taxonomy, clinical relevance, and current research status. Biomedicines 10:1760","journal-title":"Biomedicines"},{"key":"10463_CR21","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s12035-023-03671-7","volume":"61","author":"U Jain","year":"2024","unstructured":"Jain U, Johari S, Srivastava P (2024) Current insights of nanocarrier-mediated gene therapeutics to treat potential impairment of amyloid beta protein and tau protein in Alzheimer\u2019s disease. Mol Neurobiol 61:1969\u20131989","journal-title":"Mol Neurobiol"},{"key":"10463_CR22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L (2024) Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther 9:211","journal-title":"Signal Transduct Target Ther"},{"key":"10463_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2017.08.007","volume":"110","author":"AE Roher","year":"2017","unstructured":"Roher AE, Kokjohn TA, Clarke SG, Sierks MR, Maarouf CL, Serrano GE et al (2017) APP\/A\u03b2 structural diversity and Alzheimer\u2019s disease pathogenesis. Neurochem Int 110:1\u201313","journal-title":"Neurochem Int"},{"key":"10463_CR24","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429272806231020045840","author":"R Sharma","year":"2023","unstructured":"Sharma R, Abubakar MD, Bisht P, Rachamalla M, Kumar A, Murti K et al (2023) Arsenic exposure and amyloid precursor protein processing: a focus on Alzheimer\u2019s disease. Curr Mol Pharmacol. https:\/\/doi.org\/10.2174\/0118761429272806231020045840","journal-title":"Curr Mol Pharmacol"},{"key":"10463_CR25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinbiochem.2019.08.005","volume":"73","author":"R Matej","year":"2019","unstructured":"Matej R, Tesar A, Rusina R (2019) Alzheimer\u2019s disease and other neurodegenerative dementias in comorbidity: a clinical and neuropathological overview. Clin Biochem 73:26\u201331","journal-title":"Clin Biochem"},{"key":"10463_CR26","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3390\/biom12070996","volume":"12","author":"S Singh","year":"2022","unstructured":"Singh S, Yang F, Sivils A, Cegielski V, Chu X-P (2022) Amylin and secretases in the pathology and treatment of Alzheimer\u2019s disease. Biomolecules 12:996","journal-title":"Biomolecules"},{"key":"10463_CR27","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.brainresbull.2022.10.006","volume":"190","author":"DR Thal","year":"2022","unstructured":"Thal DR, Tom\u00e9 SO (2022) The central role of tau in Alzheimer\u2019s disease: from neurofibrillary tangle maturation to the induction of cell death. Brain Res Bull 190:204\u2013217","journal-title":"Brain Res Bull"},{"key":"10463_CR28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s41232-023-00277-3","volume":"43","author":"A Sobue","year":"2023","unstructured":"Sobue A, Komine O, Yamanaka K (2023) Neuroinflammation in Alzheimer\u2019s disease: microglial signature and their relevance to disease. Inflamm Regen 43:26","journal-title":"Inflamm Regen"},{"key":"10463_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","volume":"46","author":"S Thakur","year":"2023","unstructured":"Thakur S, Dhapola R, Sarma P, Medhi B, Reddy DH (2023) Neuroinflammation in Alzheimer\u2019s disease: current progress in molecular signaling and therapeutics. Inflammation 46:1\u201317","journal-title":"Inflammation"},{"key":"10463_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1117172","author":"C Wang","year":"2023","unstructured":"Wang C, Zong S, Cui X, Wang X, Wu S, Wang L et al (2023) The effects of microglia-associated neuroinflammation on Alzheimer\u2019s disease. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1117172","journal-title":"Front Immunol"},{"key":"10463_CR31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12974-023-02853-3","volume":"20","author":"Y Chen","year":"2023","unstructured":"Chen Y, Yu Y (2023) Tau and neuroinflammation in Alzheimer\u2019s disease: interplay mechanisms and clinical translation. J Neuroinflammation 20:165","journal-title":"J Neuroinflammation"},{"key":"10463_CR32","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1038\/s41380-021-01076-3","volume":"26","author":"N Brookhouser","year":"2021","unstructured":"Brookhouser N, Raman S, Frisch C, Srinivasan G, Brafman DA (2021) APOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer\u2019s disease. Mol Psychiatry 26:5715\u20135732","journal-title":"Mol Psychiatry"},{"key":"10463_CR33","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.neuron.2023.10.023","volume":"112","author":"A Litvinchuk","year":"2024","unstructured":"Litvinchuk A, Suh JH, Guo JL, Lin K, Davis SS, Bien-Ly N et al (2024) Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist. Neuron 112:384-403.e8","journal-title":"Neuron"},{"key":"10463_CR34","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.3390\/ijms24043754","volume":"24","author":"J Andrade-Guerrero","year":"2023","unstructured":"Andrade-Guerrero J, Santiago-Balmaseda A, Jeronimo-Aguilar P, Vargas-Rodr\u00edguez I, Cadena-Su\u00e1rez AR, S\u00e1nchez-Garibay C et al (2023) Alzheimer\u2019s Disease: an updated overview of its genetics. Int J Mol Sci 24:3754","journal-title":"Int J Mol Sci"},{"key":"10463_CR35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000513008","volume":"84","author":"Y Xiong","year":"2021","unstructured":"Xiong Y, Meng T, Luo J, Zhang H (2021) The Potential of neurofilament light as a biomarker in Alzheimer\u2019s disease. Eur Neurol 84:6\u201315","journal-title":"Eur Neurol"},{"issue":"1","key":"10463_CR36","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1007\/s12035-024-04285-3","volume":"62","author":"A Ortega","year":"2024","unstructured":"Ortega A, Chernicki B, Ou G, Parmar MS (2024) From lab bench to hope: emerging gene therapies in clinical trials for Alzheimer\u2019s disease. Mol Neurobiol 62(1):1112\u20131135","journal-title":"Mol Neurobiol"},{"key":"10463_CR37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ et al (2020) Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun 11:667","journal-title":"Nat Commun"},{"key":"10463_CR38","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/molecules25245789","volume":"25","author":"Z Breijyeh","year":"2020","unstructured":"Breijyeh Z, Karaman R (2020) Comprehensive review on Alzheimer\u2019s disease: causes and treatment. Molecules 25:5789","journal-title":"Molecules"},{"key":"10463_CR39","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.045211","author":"J Gamache","year":"2020","unstructured":"Gamache J, Yun Y, Chiba-Falek O (2020) Sex-dependent effect of APOE on Alzheimer\u2019s disease and other age-related neurodegenerative disorders. Dis Model Mech. https:\/\/doi.org\/10.1242\/dmm.045211","journal-title":"Dis Model Mech"},{"issue":"14","key":"10463_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/DNND.S452009","volume":"19","author":"PN Tripathi","year":"2024","unstructured":"Tripathi PN, Lodhi A, Rai SN, Nandi NK, Dumoga S, Yadav P, Tiwari AK, Singh SK, El-Shorbagi AA, Chaudhary S (2024) Review of pharmacotherapeutic targets in Alzheimer\u2019s disease and its management using traditional medicinal plants. Degener Neurol Neuromuscul Dis 19(14):47\u201374. https:\/\/doi.org\/10.2147\/DNND.S452009","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"10463_CR41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2174\/1573409913666170414123825","volume":"13","author":"SS Ahmad","year":"2017","unstructured":"Ahmad SS, Akhtar S, Danish Rizvi SM, Kamal MA, Sayeed U, Khan MKA et al (2017) Screening and elucidation of selected natural compounds for anti- Alzheimer\u2019s potential targeting BACE-1 enzyme: a case computational study. Curr Comput Aided Drug Des 13:311\u2013318","journal-title":"Curr Comput Aided Drug Des"},{"key":"10463_CR42","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00213-024-06525-9","volume":"241","author":"AMM Tarif","year":"2024","unstructured":"Tarif AMM, Huhe H, Ohno M (2024) Combination strategy employing BACE1 inhibitor and memantine to boost cognitive benefits in Alzheimer\u2019s disease therapy. Psychopharmacology 241:975\u2013986","journal-title":"Psychopharmacology"},{"key":"10463_CR43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s41983-023-00684-w","volume":"59","author":"D Hazegh Fetratjoo","year":"2023","unstructured":"Hazegh Fetratjoo D, Kargar A, Noroozian M (2023) Aducanumab: an uprising hope with vague horizons. Egypt J Neurol Psychiatry Neurosurg 59:85","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"key":"10463_CR44","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMc2111960","volume":"385","author":"B Dunn","year":"2021","unstructured":"Dunn B, Stein P, Temple R, Cavazzoni P (2021) An Appropriate use of accelerated approval \u2014 aducanumab for Alzheimer\u2019s disease. N Engl J Med 385:856\u2013857","journal-title":"N Engl J Med"},{"issue":"7","key":"10463_CR45","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1007\/s12035-020-01945-y","volume":"57","author":"SN Rai","year":"2020","unstructured":"Rai SN, Singh C, Singh A, Singh MP, Singh BK (2020) Mitochondrial dysfunction: a potential therapeutic target to treat Alzheimer\u2019s disease. Mol Neurobiol 57(7):3075\u20133088. https:\/\/doi.org\/10.1007\/s12035-020-01945-y","journal-title":"Mol Neurobiol"},{"key":"10463_CR46","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.2174\/0929867331666230727103553","volume":"31","author":"S Ashique","year":"2024","unstructured":"Ashique S, Sirohi E, Kumar S, Rihan M, Mishra N, Bhatt S et al (2024) Aducanumab in Alzheimer\u2019s disease: a critical update. Curr Med Chem 31:5004\u20135026","journal-title":"Curr Med Chem"},{"key":"10463_CR47","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2004.6.3\/galexander","volume":"6","author":"GE Alexander","year":"2004","unstructured":"Alexander GE (2004) Biology of Parkinson\u2019s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci 6:259\u2013280","journal-title":"Dialogues Clin Neurosci"},{"key":"10463_CR48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/00207454.2018.1486837","volume":"129","author":"AU Khan","year":"2019","unstructured":"Khan AU, Akram M, Daniyal M, Zainab R (2019) Awareness and current knowledge of Parkinson\u2019s disease: a neurodegenerative disorder. Int J Neurosci 129:55\u201393","journal-title":"Int J Neurosci"},{"key":"10463_CR49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fncel.2015.00124","volume":"9","author":"M Chin-Chan","year":"2015","unstructured":"Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B (2015) Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci 9:124","journal-title":"Front Cell Neurosci"},{"key":"10463_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10654-011-9581-6","volume":"26","author":"K Wirdefeldt","year":"2011","unstructured":"Wirdefeldt K, Adami H-O, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of Parkinson\u2019s disease: a review of the evidence. Eur J Epidemiol 26:1\u201358","journal-title":"Eur J Epidemiol"},{"key":"10463_CR51","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/jnnp.2004.060186","volume":"76","author":"SM Hague","year":"2005","unstructured":"Hague SM (2005) Neurodegenerative disorders: Parkinson\u2019s disease and Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 76:1058\u20131063","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10463_CR52","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397:2284\u20132303","journal-title":"Lancet"},{"key":"10463_CR53","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.stem.2023.05.015","volume":"30","author":"MS Kim","year":"2023","unstructured":"Kim MS, Ra EA, Kweon SH, Seo BA, Ko HS, Oh Y et al (2023) Advanced human iPSC-based preclinical model for Parkinson\u2019s disease with optogenetic alpha-synuclein aggregation. Cell Stem Cell 30:973-986.e11","journal-title":"Cell Stem Cell"},{"key":"10463_CR54","doi-asserted-by":"crossref","first-page":"155511","DOI":"10.1016\/j.prp.2024.155511","volume":"261","author":"L Thangavelu","year":"2024","unstructured":"Thangavelu L, Moglad E, Afzal M, Almalki WH, Malathi H, Bansal P et al (2024) Non-coding RNAs in Parkinson\u2019s disease: regulating SNCA and alpha-synuclein aggregation. Pathol Res Pract 261:155511","journal-title":"Pathol Res Pract"},{"key":"10463_CR55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.15698\/cst2018.10.158","volume":"2","author":"M Valera-Alberni","year":"2018","unstructured":"Valera-Alberni M, Canto C (2018) Mitochondrial stress management: a dynamic journey. Cell Stress 2:253\u2013274","journal-title":"Cell Stress"},{"key":"10463_CR56","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.4103\/1673-5374.300980","volume":"16","author":"J Dorszewska","year":"2021","unstructured":"Dorszewska J, Kowalska M, Prendecki M, Piekut T, Koz\u0142owska J, Kozubski W (2021) Oxidative stress factors in Parkinson\u2019s disease. Neural Regen Res 16:1383","journal-title":"Neural Regen Res"},{"key":"10463_CR57","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3164\/jcbn.13-108","volume":"54","author":"Y Saito","year":"2014","unstructured":"Saito Y (2014) Oxidized DJ-1 as a possible biomarker of Parkinson\u2019s disease. J Clin Biochem Nutr 54:138\u2013144","journal-title":"J Clin Biochem Nutr"},{"key":"10463_CR58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13041-017-0340-9","volume":"10","author":"L Puspita","year":"2017","unstructured":"Puspita L, Chung SY, Shim J (2017) Oxidative stress and cellular pathologies in Parkinson\u2019s disease. Mol Brain 10:53","journal-title":"Mol Brain"},{"key":"10463_CR59","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/antiox9070597","volume":"9","author":"K-H Chang","year":"2020","unstructured":"Chang K-H, Chen C-M (2020) The role of oxidative stress in Parkinson\u2019s disease. Antioxidants 9:597","journal-title":"Antioxidants"},{"key":"10463_CR60","doi-asserted-by":"crossref","first-page":"793","DOI":"10.31128\/AJGP-07-21-6087","volume":"50","author":"S Waller","year":"2021","unstructured":"Waller S, Williams L, Morales-Brice\u00f1o H, Fung VS (2021) The initial diagnosis and management of Parkinson\u2019s disease. Aust J Gen Pract 50:793\u2013800","journal-title":"Aust J Gen Pract"},{"key":"10463_CR61","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1515\/CCLM.2011.077","volume":"49","author":"M Eller","year":"2011","unstructured":"Eller M, Williams DR (2011) \u03b1-Synuclein in Parkinson disease and other neurodegenerative disorders. Clin Chem Lab Med 49:403\u2013408","journal-title":"Clin Chem Lab Med"},{"key":"10463_CR62","first-page":"451","volume":"14","author":"ER Dorsey","year":"2024","unstructured":"Dorsey ER, Bloem BR (2024) Parkinson\u2019s Disease is predominantly an environmental disease. J Park Dis 14:451\u2013465","journal-title":"J Park Dis"},{"key":"10463_CR63","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.neuro.2012.01.011","volume":"33","author":"A Kanthasamy","year":"2012","unstructured":"Kanthasamy A, Jin H, Anantharam V, Sondarva G, Rangasamy V, Rana A et al (2012) Emerging neurotoxic mechanisms in environmental factors-induced neurodegeneration. Neurotoxicology 33:833\u2013837","journal-title":"Neurotoxicology"},{"key":"10463_CR64","doi-asserted-by":"crossref","first-page":"11059","DOI":"10.3390\/ijms231911059","volume":"23","author":"M Naoi","year":"2022","unstructured":"Naoi M, Maruyama W, Shamoto-Nagai M (2022) Neuroprotective function of rasagiline and selegiline, inhibitors of type B monoamine oxidase, and role of monoamine oxidases in synucleinopathies. Int J Mol Sci 23:11059","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10463_CR65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/alz.12004","volume":"16","author":"HJ Rosen","year":"2020","unstructured":"Rosen HJ, Boeve BF, Boxer AL (2020) Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: recent findings from ARTFL and LEFFTDS. Alzheimers Dement 16(1):71\u201378","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10463_CR66","doi-asserted-by":"crossref","first-page":"fcad280","DOI":"10.1093\/braincomms\/fcad280","volume":"5","author":"JJ Llibre-Guerra","year":"2023","unstructured":"Llibre-Guerra JJ, Iaccarino L, Coble D, Edwards L, Li Y, McDade E, Strom A, Gordon B, Mundada N, Schindler SE, Tsoy E (2023) Longitudinal clinical, cognitive and biomarker profiles in dominantly inherited versus sporadic early-onset Alzheimer\u2019s disease. Brain Commun 5(6):fcad280","journal-title":"Brain Commun"},{"issue":"3","key":"10463_CR67","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/brain\/awac399","volume":"146","author":"C Johansson","year":"2023","unstructured":"Johansson C, Thordardottir S, Laffita-Mesa J, Rodriguez-Vieitez E, Zetterberg H, Blennow K, Graff C (2023) Plasma biomarker profiles in autosomal dominant Alzheimer\u2019s disease. Brain 146(3):1132\u20131140","journal-title":"Brain"},{"key":"10463_CR68","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2174\/1871527319666200722153156","volume":"19","author":"H Bogetofte","year":"2020","unstructured":"Bogetofte H, Alamyar A, Blaabjerg M, Meyer M (2020) Levodopa therapy for Parkinson\u2019s Disease: history, current status and perspectives. CNS Neurol Disord Drug Targets 19:572\u2013583","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10463_CR69","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00702-020-02142-w","volume":"127","author":"JPM Finberg","year":"2020","unstructured":"Finberg JPM (2020) The discovery and development of rasagiline as a new anti-Parkinson medication. J Neural Transm 127:125\u2013130","journal-title":"J Neural Transm"},{"key":"10463_CR70","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB et al (2024) Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease. Nat Med 30:1096\u20131103","journal-title":"Nat Med"},{"key":"10463_CR71","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1038\/s41591-024-03270-6","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T et al (2024) Sustained effect of prasinezumab on Parkinson\u2019s disease motor progression in the open-label extension of the PASADENA trial. Nat Med 30:3669\u20133675","journal-title":"Nat Med"},{"key":"10463_CR72","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13024-023-00685-6","volume":"19","author":"KE Irwin","year":"2024","unstructured":"Irwin KE, Sheth U, Wong PC, Gendron TF (2024) Fluid biomarkers for amyotrophic lateral sclerosis: a review. Mol Neurodegener 19:9","journal-title":"Mol Neurodegener"},{"key":"10463_CR73","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/ene.14393","volume":"27","author":"P Masrori","year":"2020","unstructured":"Masrori P, Van Damme P (2020) Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 27:1918\u20131929","journal-title":"Eur J Neurol"},{"key":"10463_CR74","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","volume":"400","author":"EL Feldman","year":"2022","unstructured":"Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ et al (2022) Amyotrophic lateral sclerosis. Lancet 400:1363\u20131380","journal-title":"Lancet"},{"key":"10463_CR75","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3390\/biom14101324","volume":"14","author":"M Perni","year":"2024","unstructured":"Perni M, Mannini B (2024) Targeting protein aggregation in ALS. Biomolecules 14:1324","journal-title":"Biomolecules"},{"key":"10463_CR76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1326-9-43","volume":"9","author":"S Moussaud","year":"2014","unstructured":"Moussaud S, Jones DR, Moussaud-Lamodi\u00e8re EL, Delenclos M, Ross OA, McLean PJ (2014) Alpha-synuclein and tau: teammates in neurodegeneration? Mol Neurodegener 9:1\u20134","journal-title":"Mol Neurodegener"},{"issue":"s2","key":"10463_CR77","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3233\/JAD-2011-110182","volume":"24","author":"BS Gadad","year":"2011","unstructured":"Gadad BS, Britton GB, Rao KS (2011) Targeting oligomers in neurodegenerative disorders: lessons from \u03b1-synuclein, tau, and amyloid-\u03b2 peptide. J Alzheimers Dis 24(s2):223\u2013232","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10463_CR78","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13195-022-01150-0","volume":"14","author":"KH Shim","year":"2022","unstructured":"Shim KH, Kang MJ, Youn YC, An SS, Kim S (2022) Alpha-synuclein: a pathological factor with A\u03b2 and tau and biomarker in Alzheimer\u2019s disease. Alzheimers Res Ther 14(1):201","journal-title":"Alzheimers Res Ther"},{"key":"10463_CR79","doi-asserted-by":"crossref","first-page":"1383453","DOI":"10.3389\/fmolb.2024.1383453","volume":"11","author":"M Tsekrekou","year":"2024","unstructured":"Tsekrekou M, Giannakou M, Papanikolopoulou K, Skretas G (2024) Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS. Front Mol Biosci 11:1383453","journal-title":"Front Mol Biosci"},{"key":"10463_CR80","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1007\/s00415-024-12485-z","volume":"271","author":"H Wang","year":"2024","unstructured":"Wang H, Zeng R (2024) Aberrant protein aggregation in amyotrophic lateral sclerosis. J Neurol 271:4826\u20134851","journal-title":"J Neurol"},{"key":"10463_CR81","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12964-024-01791-8","volume":"22","author":"O Kosz\u0142a","year":"2024","unstructured":"Kosz\u0142a O, So\u0142ek P (2024) Misfolding and aggregation in neurodegenerative diseases: protein quality control machinery as potential therapeutic clearance pathways. Cell Commun Signal 22:421","journal-title":"Cell Commun Signal"},{"key":"10463_CR82","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.3390\/ijms25115587","volume":"25","author":"FJ Arnold","year":"2024","unstructured":"Arnold FJ, Putka AF, Raychaudhuri U, Hsu S, Bedlack RS, Bennett CL et al (2024) Revisiting glutamate excitotoxicity in amyotrophic lateral sclerosis and age-related neurodegeneration. Int J Mol Sci 25:5587","journal-title":"Int J Mol Sci"},{"key":"10463_CR83","doi-asserted-by":"crossref","first-page":"15430","DOI":"10.3390\/ijms242015430","volume":"24","author":"F Provenzano","year":"2023","unstructured":"Provenzano F, Torazza C, Bonifacino T, Bonanno G, Milanese M (2023) The key role of astrocytes in amyotrophic lateral sclerosis and their commitment to glutamate excitotoxicity. Int J Mol Sci 24:15430","journal-title":"Int J Mol Sci"},{"key":"10463_CR84","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s10038-022-01055-8","volume":"68","author":"N Suzuki","year":"2023","unstructured":"Suzuki N, Nishiyama A, Warita H, Aoki M (2023) Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy. J Hum Genet 68:131\u2013152","journal-title":"J Hum Genet"},{"key":"10463_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1177431","author":"Q-Q Duan","year":"2023","unstructured":"Duan Q-Q, Jiang Z, Su W-M, Gu X-J, Wang H, Cheng Y-F et al (2023) Risk factors of amyotrophic lateral sclerosis: a global meta-summary. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2023.1177431","journal-title":"Front Neurosci"},{"key":"10463_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1108383","author":"D Saucier","year":"2023","unstructured":"Saucier D, Registe PPW, B\u00e9langer M, O\u2019Connell C (2023) Urbanization, air pollution, and water pollution: identification of potential environmental risk factors associated with amyotrophic lateral sclerosis using systematic reviews. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2023.1108383","journal-title":"Front Neurol"},{"key":"10463_CR87","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1007\/s10072-023-06869-8","volume":"44","author":"AZ Nourelden","year":"2023","unstructured":"Nourelden AZ, Kamal I, Hagrass AI, Tawfik AG, Elhady MM, Fathallah AH et al (2023) Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci 44:3429\u20133442","journal-title":"Neurol Sci"},{"key":"10463_CR88","doi-asserted-by":"crossref","first-page":"8426","DOI":"10.1038\/s41467-024-52539-4","volume":"15","author":"D Hollingworth","year":"2024","unstructured":"Hollingworth D, Thomas F, Page DA, Fouda MA, De Castro RLR, Sula A et al (2024) Structural basis for the rescue of hyperexcitable cells by the amyotrophic lateral sclerosis drug Riluzole. Nat Commun 15:8426","journal-title":"Nat Commun"},{"key":"10463_CR89","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s13760-024-02476-2","volume":"124","author":"S-L Huang","year":"2024","unstructured":"Huang S-L, Shen Y-L, Peng W-Y, Ye K, Zheng H (2024) Edaravone for patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Acta Neurol Belg 124:895\u2013904","journal-title":"Acta Neurol Belg"},{"key":"10463_CR90","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.mayocp.2018.04.007","volume":"93","author":"B Oskarsson","year":"2018","unstructured":"Oskarsson B, Gendron TF, Staff NP (2018) Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc 93:1617\u20131628","journal-title":"Mayo Clin Proc"},{"key":"10463_CR91","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16264","author":"P Van Damme","year":"2024","unstructured":"Van Damme P, Al-Chalabi A, Andersen PM, Chi\u00f2 A, Couratier P, De Carvalho M et al (2024) European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD). Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.16264","journal-title":"Eur J Neurol"},{"key":"10463_CR92","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/14737175.2024.2355983","volume":"24","author":"M Oliveira Santos","year":"2024","unstructured":"Oliveira Santos M, de Carvalho M (2024) Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis. Expert Rev Neurother 24:549\u2013553","journal-title":"Expert Rev Neurother"},{"key":"10463_CR93","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3390\/genes15101342","volume":"15","author":"H Moriyama","year":"2024","unstructured":"Moriyama H, Yokota T (2024) Recent progress of antisense oligonucleotide therapy for superoxide-dismutase-1-mutated amyotrophic lateral sclerosis: focus on tofersen. Genes (Basel) 15:1342","journal-title":"Genes (Basel)"},{"key":"10463_CR94","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.3390\/ijms25115707","volume":"25","author":"S Dabrowska","year":"2024","unstructured":"Dabrowska S, Turano E, Scambi I, Virla F, Nodari A, Pezzini F et al (2024) A cellular model of amyotrophic lateral sclerosis to study the therapeutic effects of extracellular vesicles from adipose mesenchymal stem cells on microglial activation. Int J Mol Sci 25:5707","journal-title":"Int J Mol Sci"},{"key":"10463_CR95","doi-asserted-by":"crossref","unstructured":"Parsons MP, Raymond LA (2023) Huntington disease. Neurobiol brain disord. Elsevier, pp 275\u2013292","DOI":"10.1016\/B978-0-323-85654-6.00042-3"},{"key":"10463_CR96","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13250","author":"S P\u00e9rez-Oliveira","year":"2024","unstructured":"P\u00e9rez-Oliveira S, Castilla-Silgado J, Painous C, Aldecoa I, Men\u00e9ndez-Gonz\u00e1lez M, Bl\u00e1zquez-Estrada M et al (2024) Huntingtin CAG repeats in neuropathologically confirmed tauopathies: novel insights. Brain Pathol. https:\/\/doi.org\/10.1111\/bpa.13250","journal-title":"Brain Pathol"},{"key":"10463_CR97","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2174\/1389450115666140115113734","volume":"15","author":"J Gil-Mohapel","year":"2014","unstructured":"Gil-Mohapel J, Brocardo P, Christie B (2014) The role of oxidative stress in huntington\u2019s disease: are antioxidants good therapeutic candidates? Curr Drug Targets 15:454\u2013468","journal-title":"Curr Drug Targets"},{"key":"10463_CR98","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/JHD-200427","volume":"10","author":"EP Hong","year":"2021","unstructured":"Hong EP, MacDonald ME, Wheeler VC, Jones L, Holmans P, Orth M et al (2021) Huntington\u2019s disease pathogenesis: two sequential components. J Huntingtons Dis 10:35\u201351","journal-title":"J Huntingtons Dis"},{"key":"10463_CR99","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"RAC Roos","year":"2010","unstructured":"Roos RAC (2010) Huntington\u2019s disease: a clinical review. Orphanet J Rare Dis 5:40","journal-title":"Orphanet J Rare Dis"},{"key":"10463_CR100","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.3390\/ijms25073845","volume":"25","author":"H Tong","year":"2024","unstructured":"Tong H, Yang T, Xu S, Li X, Liu L, Zhou G et al (2024) Huntington\u2019s disease: complex pathogenesis and therapeutic strategies. Int J Mol Sci 25:3845","journal-title":"Int J Mol Sci"},{"key":"10463_CR101","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ajhg.2022.03.004","volume":"109","author":"J-M Lee","year":"2022","unstructured":"Lee J-M, Huang Y, Orth M, Gillis T, Siciliano J, Hong E et al (2022) Genetic modifiers of Huntington disease differentially influence motor and cognitive domains. Am J Hum Genet 109:885\u2013899","journal-title":"Am J Hum Genet"},{"key":"10463_CR102","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/mds.29228","volume":"37","author":"A Medina","year":"2022","unstructured":"Medina A, Mahjoub Y, Shaver L, Pringsheim T (2022) Prevalence and incidence of Huntington\u2019s disease: an updated systematic review and meta-analysis. Mov Disord 37:2327\u20132335","journal-title":"Mov Disord"},{"key":"10463_CR103","doi-asserted-by":"crossref","first-page":"e70053","DOI":"10.1111\/cns.70053","volume":"30","author":"AA Bhat","year":"2024","unstructured":"Bhat AA, Moglad E, Afzal M, Thapa R, Almalki WH, Kazmi I et al (2024) Therapeutic approaches targeting aging and cellular senescence in Huntington\u2019s disease. CNS Neurosci Ther 30:e70053","journal-title":"CNS Neurosci Ther"},{"key":"10463_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061432","author":"A Jurcau","year":"2022","unstructured":"Jurcau A (2022) Molecular pathophysiological mechanisms in Huntington\u2019s disease. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10061432","journal-title":"Biomedicines"},{"key":"10463_CR105","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3390\/genes15060807","volume":"15","author":"M Pengo","year":"2024","unstructured":"Pengo M, Squitieri F (2024) Beyond CAG repeats: the multifaceted role of genetics in huntington disease. Genes (Basel) 15:807","journal-title":"Genes (Basel)"},{"key":"10463_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2024.01.001","author":"E Cubo","year":"2024","unstructured":"Cubo E, Rivadeneyra J, Sim\u00f3n-Vicente L, Aguado L, Calvo S, Saiz-Rodr\u00edguez M et al (2024) The association between lifestyle factors and mortality in Huntington\u2019s disease. Neurologia. https:\/\/doi.org\/10.1016\/j.nrl.2024.01.001","journal-title":"Neurologia"},{"key":"10463_CR107","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/mdc3.14230","volume":"11","author":"S Feleus","year":"2024","unstructured":"Feleus S, Skotnicki LEM, Roos RAC, de Bot ST (2024) Medication use and treatment indications in Huntington\u2019s disease; analyses from a large cohort. Mov Disord Clin Pract 11:1530\u20131541","journal-title":"Mov Disord Clin Pract"},{"key":"10463_CR108","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/jpm13030385","volume":"13","author":"X Garc\u00eda-Gonz\u00e1lez","year":"2023","unstructured":"Garc\u00eda-Gonz\u00e1lez X, Cubo E, Sim\u00f3n-Vicente L, Mariscal N, Alcaraz R, Aguado L et al (2023) Pharmacogenetics in the treatment of Huntington\u2019s disease: review and future perspectives. J Pers Med 13:385","journal-title":"J Pers Med"},{"key":"10463_CR109","doi-asserted-by":"crossref","first-page":"13021","DOI":"10.3390\/ijms241613021","volume":"24","author":"A Jiang","year":"2023","unstructured":"Jiang A, Handley RR, Lehnert K, Snell RG (2023) From pathogenesis to therapeutics: a review of 150 years of Huntington\u2019s disease research. Int J Mol Sci 24:13021","journal-title":"Int J Mol Sci"},{"key":"10463_CR110","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/B978-0-323-95672-7.00015-7","volume-title":"Huntington\u2019s Dis","author":"BR Leavitt","year":"2024","unstructured":"Leavitt BR (2024) Current clinical trials of new therapeutic agents for Huntington\u2019s disease. In: Yang XW, Thompson LM, Heiman M (eds) Huntington\u2019s Dis. Elsevier, Amsterdam, pp 571\u2013589"},{"key":"10463_CR111","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, Scahill RI, Wild EJ et al (2022) Potential disease-modifying therapies for Huntington\u2019s disease: lessons learned and future opportunities. Lancet Neurol 21:645\u2013658","journal-title":"Lancet Neurol"},{"key":"10463_CR112","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11910-024-01345-y","volume":"24","author":"J Saade","year":"2024","unstructured":"Saade J, Mestre TA (2024) Huntington\u2019s disease: latest frontiers in therapeutics. Curr Neurol Neurosci Rep 24:255\u2013264","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10463_CR113","doi-asserted-by":"crossref","first-page":"106049","DOI":"10.1016\/j.parkreldis.2024.106049","volume":"122","author":"C Sampaio","year":"2024","unstructured":"Sampaio C (2024) Huntington disease \u2013 update on ongoing therapeutic developments and a look toward the future. Parkinsonism Relat Disord 122:106049","journal-title":"Parkinsonism Relat Disord"},{"key":"10463_CR114","first-page":"1","volume":"4","author":"A Rahman","year":"2024","unstructured":"Rahman A, Banu Z, Rani R, Mehdiya R (2024) Unravelling Alzheimer\u2019s disease: insights into pathophysiology, etiology, diagnostic approaches, and the promise of aducanumab, lecanemab, and donanemab. J Phytonanotechnology Pharm Sci 4:1\u201310","journal-title":"J Phytonanotechnology Pharm Sci"},{"key":"10463_CR115","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2174\/1389450123666220526155144","volume":"23","author":"A Malaiya","year":"2022","unstructured":"Malaiya A, Singhai M, Singh M, Prajapati SK, Choudhury H, Fatima M et al (2022) Recent update on the Alzheimer\u2019s disease progression, diagnosis and treatment approaches. Curr Drug Targets 23:978\u20131001","journal-title":"Curr Drug Targets"},{"key":"10463_CR116","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s10072-023-07205-w","volume":"45","author":"CHF Camargo","year":"2024","unstructured":"Camargo CHF, Ferreira-Peruzzo SA, Ribas DIR, Franklin GL, Teive HAG (2024) Imbalance and gait impairment in Parkinson\u2019s disease: discussing postural instability and ataxia. Neurol Sci 45:1377\u20131388","journal-title":"Neurol Sci"},{"key":"10463_CR117","doi-asserted-by":"crossref","unstructured":"Oliveira IC, dos Santos TA, Covizzi IVB, Scalon T, B\u00f4as JRV, Andrade FEC, et al (2024) \u03b1-Synuclein Aggregates and Parkinson\u2019s disease. Eyes Heal Sci V02. Seven Editora, pp 703\u2013719","DOI":"10.56238\/sevened2024.001-055"},{"key":"10463_CR118","doi-asserted-by":"crossref","first-page":"9966","DOI":"10.3390\/ijms25189966","volume":"25","author":"RE Rizea","year":"2024","unstructured":"Rizea RE, Corlatescu A-D, Costin HP, Dumitru A, Ciurea AV (2024) Understanding amyotrophic lateral sclerosis: pathophysiology, diagnosis, and therapeutic advances. Int J Mol Sci 25:9966","journal-title":"Int J Mol Sci"},{"key":"10463_CR119","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/med.21974","volume":"43","author":"MF Elmansy","year":"2023","unstructured":"Elmansy MF, Reidl CT, Rahaman M, \u00d6zdinler PH, Silverman RB (2023) Small molecules targeting different cellular pathologies for the treatment of amyotrophic lateral sclerosis. Med Res Rev 43:2260\u20132302","journal-title":"Med Res Rev"},{"key":"10463_CR120","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.4103\/1673-5374.382985","volume":"19","author":"Y Hu","year":"2024","unstructured":"Hu Y, Chen W, Wei C, Jiang S, Li S, Wang X et al (2024) Pathological mechanisms of amyotrophic lateral sclerosis. Neural Regen Res 19:1036\u20131044","journal-title":"Neural Regen Res"},{"key":"10463_CR121","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nn.3584","volume":"17","author":"AE Renton","year":"2014","unstructured":"Renton AE, Chi\u00f2 A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17:17\u201323","journal-title":"Nat Neurosci"},{"key":"10463_CR122","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00702-024-02794-y","volume":"131","author":"KA Jellinger","year":"2024","unstructured":"Jellinger KA (2024) Pathomechanisms of behavioral abnormalities in Huntington disease: an update. J Neural Transm 131:999\u20131012","journal-title":"J Neural Transm"},{"key":"10463_CR123","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00702-024-02744-8","volume":"131","author":"KA Jellinger","year":"2024","unstructured":"Jellinger KA (2024) Mild cognitive impairment in Huntington\u2019s disease: challenges and outlooks. J Neural Transm 131:289\u2013304","journal-title":"J Neural Transm"},{"issue":"6","key":"10463_CR124","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1053\/j.sult.2020.08.011","volume":"41","author":"PA Rowley","year":"2020","unstructured":"Rowley PA, Samsonov AA, Betthauser TJ, Pirasteh A, Johnson SC, Eisenmenger LB (2020) Amyloid and tau PET imaging of Alzheimer disease and other neurodegenerative conditions. Semin Ultrasound CT MRI 41(6):572\u2013583","journal-title":"Semin Ultrasound CT MRI"},{"issue":"1","key":"10463_CR125","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/brain\/awaa365","volume":"144","author":"D Arnaldi","year":"2021","unstructured":"Arnaldi D, Chincarini A, Hu MT, Sonka K, Boeve B, Miyamoto T, Puligheddu M, De Cock VC, Terzaghi M, Plazzi G, Tachibana N (2021) Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain 144(1):278\u2013287","journal-title":"Brain"},{"issue":"3","key":"10463_CR126","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.3390\/ijms24031911","volume":"24","author":"A Behler","year":"2023","unstructured":"Behler A, M\u00fcller H-P, Ludolph AC, Kassubek J (2023) Diffusion tensor imaging in amyotrophic lateral sclerosis: machine learning for biomarker development. Int J Mol Sci 24(3):1911. https:\/\/doi.org\/10.3390\/ijms24031911","journal-title":"Int J Mol Sci"},{"key":"10463_CR127","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.15815","author":"D Xiao","year":"2022","unstructured":"Xiao D, Wang K, Theriault L, Charbel E, Alzheimer\u2019s Disease Neuroimaging Initiative (2022) White matter integrity and key structures affected in Alzheimer\u2019s disease characterized by diffusion tensor imaging. Eur J Neurosci. https:\/\/doi.org\/10.1111\/ejn.15815","journal-title":"Eur J Neurosci"},{"key":"10463_CR128","unstructured":"Pleen J, Camerucci E, Al-Sabbagh MQ, Cunningham K (2024) Blood-based biomarkers in Alzheimer disease: clinical implementation and limitations. Practical Neurology (US). 23(2):27\u201329,35\u201339"},{"issue":"2","key":"10463_CR129","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3233\/JAD-230932","volume":"96","author":"Y Dong","year":"2023","unstructured":"Dong Y, Hou T, Li Y, Liu R, Cong L, Liu K, Liu C, Han X, Ren Y, Tang S, Winblad B, Blennow K, Wang Y, Du Y, Qiu C (2023) Plasma amyloid-\u03b2, total tau, and neurofilament light chain across the Alzheimer\u2019s disease clinical spectrum: a population-based study. J Alzheimers Dis 96(2):845\u2013858. https:\/\/doi.org\/10.3233\/JAD-230932","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"10463_CR130","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3390\/jpm12050770","volume":"12","author":"G Gentile","year":"2022","unstructured":"Gentile G, Morello G, La Cognata V, Guarnaccia M, Conforti FL, Cavallaro S (2022) Dysregulated miRNAs as biomarkers and therapeutical targets in neurodegenerative diseases. J Pers Med 12(5):770. https:\/\/doi.org\/10.3390\/jpm12050770","journal-title":"J Pers Med"},{"key":"10463_CR131","doi-asserted-by":"publisher","first-page":"119","DOI":"10.37349\/ent.2024.00075","volume":"4","author":"S Selvam","year":"2024","unstructured":"Selvam S, Ayyavoo V (2024) Biomarkers in neurodegenerative diseases: a broad overview. Explor Neuroprot Ther 4:119\u2013147. https:\/\/doi.org\/10.37349\/ent.2024.00075","journal-title":"Explor Neuroprot Ther"},{"key":"10463_CR132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10654-011-9581-6","volume":"26","author":"K Wirdefeldt","year":"2011","unstructured":"Wirdefeldt K, Adami H-O, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiologyof Parkinson\u2019s disease: a review of the evidence. Eur J Epidemiol 26:1\u201358","journal-title":"Eur J Epidemiol"},{"key":"10463_CR133","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s10571-024-01496-z","volume":"44","author":"R Kearns","year":"2024","unstructured":"Kearns R (2024) Gut-brain axis and neuroinflammation: the role of gut permeability and the kynurenine pathway in neurological disorders. Cell Mol Neurobiol 44:64. https:\/\/doi.org\/10.1007\/s10571-024-01496-z","journal-title":"Cell Mol Neurobiol"},{"issue":"14","key":"10463_CR134","doi-asserted-by":"publisher","first-page":"1133546","DOI":"10.3389\/fneur.2023.1133546","volume":"20","author":"D Hong","year":"2023","unstructured":"Hong D, Zhang C, Wu W, Lu X, Zhang L (2023) Modulation of the gut-brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis. Front Neurol 20(14):1133546. https:\/\/doi.org\/10.3389\/fneur.2023.1133546","journal-title":"Front Neurol"},{"issue":"1","key":"10463_CR135","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/nu17010102","volume":"17","author":"F Cuffaro","year":"2024","unstructured":"Cuffaro F, Lamminp\u00e4\u00e4 I, Niccolai E, Amedei A (2024) Nutritional and microbiota-based approaches in amyotrophic lateral sclerosis: from prevention to treatment. Nutrients 17(1):102. https:\/\/doi.org\/10.3390\/nu17010102","journal-title":"Nutrients"},{"key":"10463_CR136","doi-asserted-by":"publisher","first-page":"9558","DOI":"10.1038\/s41598-024-59250-w","volume":"14","author":"ZSW Chui","year":"2024","unstructured":"Chui ZSW, Chan LML, Zhang EWH et al (2024) Effects of microbiome-based interventions on neurodegenerative diseases: a systematic review and meta-analysis. Sci Rep 14:9558. https:\/\/doi.org\/10.1038\/s41598-024-59250-w","journal-title":"Sci Rep"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10463-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10463-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10463-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:24:37Z","timestamp":1766852677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10463-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":136,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10463"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10463-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"4 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"This research did not involve the use of animals or humans.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal participants"}}],"article-number":"337"}}